Review article: the treatment of Helicobacter pylori infection

Alimentary Pharmacology & Therapeutics

Volumn 6, Issue 3, 1992, Pages 291-303

  HEATLEY, R V ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTI ULCER AGENTS; ANTIULCER AGENT; BISMUTH CITRATE; METRONIDAZOLE; ORGANOMETALLIC COMPOUND; ANTACID AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BISMUTH DERIVATIVE; BISMUTH SALICYLATE; BISMUTH SALT; ERYTHROMYCIN; GASTROINTESTINAL AGENT; GENTAMICIN; HISTAMINE H2 RECEPTOR ANTAGONIST; MACROLIDE; NITROFURANTOIN DERIVATIVE; OFLOXACIN; PROSTAGLANDIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SUCRALFATE; TETRACYCLINE; TINIDAZOLE; UNCLASSIFIED DRUG;

DRUG COMBINATION; DUODENUM ULCER; DYSPEPSIA; GASTRITIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; REVIEW; ANTIBACTERIAL ACTIVITY; HUMAN; INFECTION; PEPTIC ULCER;

AMOXICILLIN; ANTI-ULCER AGENTS; DRUG THERAPY, COMBINATION; DUODENAL ULCER; DYSPEPSIA; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; METRONIDAZOLE; ORGANOMETALLIC COMPOUNDS;

EID: 0026874753     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.1992.tb00051.x     Document Type: Review

References (82)

1. Campylobacter pylori: treatment of gastritis
2. Campylobacter pylori and ulcer treatment
3. Campylobacter pyloridis and associated gastritis; investigator blind, placebo controlled trial of bismuth salicyclate and erythromycin ethylsucciriate
4. Campylobacter pyloridis‐associated chronic active antral gastritis
5. Campylobacter pylori and non‐ulcer dyspepsia
6. Campylobacter pylori and history of dyspepsia in healthy blood donors
7. Prevalance of Helicobacter pylori infection and histologic gastritis in asymptomatic persons
8. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration
9. Nervous dyspepsia (Letter)
10. Symptomatology in C. pylori‐positive and ‐negative non‐ulcer dyspepsia
11. Use of endoscopy in patients with dyspepsia
12. Campylobacter pylori in peptic ulcer disease. III. Symptoms and paraclinical and epidemiologic findings
13. C. pylori is not associated with a distinct dyspeptic syndrome
14. Campylobacter pylori—a role in non‐ulcer dyspepsia
15. Effect of colloidal bismuth sub‐citrate on symptoms and gastric histology in non‐ulcer dyspepsia. A double‐blind placebo‐controlled study
16. Dyspeptic symptoms improve following eradication of gastric Campylobacter pyloridis
17. Non‐ulcer dyspepsia and short‐term De‐Nol therapy: a placebo‐controlled trial with particular reference to the role of Campylobacter pylori
18. Campylobacter‐associated gastritis in patients with non‐uncler dyspepsia: a double‐blind placebo‐controlled trial with colloidal bismuth subcitrate
19. A randomised controlled trial of eradication of Helicobacter pylori on the symptoms of non‐ulcer dyspepsia
20. Amoxycillin and colloidal bismuth sub‐citrate improve associated gastritis but not symptoms in patients with non‐ulcer dyspepsia
21. Campylobacter pylori‐associated gastritis: a double‐blind placebo‐controlled trial with amoxycillin
22. Nitrofurans in the treatment of gastritis associated with Campylobacter pylori
23. Prophylactic effect of cimetidine in duodenal ulcer disease
24. Gastric acid
25. The historical association between bacteria and peptic‐ulcer disease
26. The presence of spirochaetes in human gastric mucosa
27. Double‐blind short‐term trial of furazolidone in peptic ulcer
28. Furazolidone in peptic ulcer
29. Helicobacter pylori and peptic ulceration: histopathological aspects
30. Campylobacter pylori and duodenal ulcers: the gastrin link
31. Lowered gastrin and gastric acidity after eradication of Campylobacter pylori in duodenal ulcer
32. Campylobacter pyloridis and acid induced gastric metaplasia in the pathogenesis of duodenitis
33. Mucosal IgA recognition of Heliobacter pylori 120 kDa protein, peptic ulceration and gastric pathology
34. Difference in relapse rates of duodenal ulcer after healing with cimetidine or tripotassium dicitrato bismuthate
35. Cimetidine and colloidal bismuth subcitrate in the treatment of chronic duodenal ulcer, comparison of initial healing and recurrence after healing
36. Comparison of cimetidine and tripotassium dicitrato bismuthate in healing and relapse of duodenal ulcers
37. Healing and recurrence of duodenal ulcer after treatment with tripotassium dicitrato bismuthate (TDB) tablets or cimetidine
38. Campylobacter pylori and recurrence of duodenal ulcers—12 months follow‐up study
39. A comparison of ranitidine and tripotassium dicitrato bismuthate (TDB) in relapse rates of duodenal ulcer. The role of Campylobacter pylori (CP)
40. Relapse rates in duodenal ulcer patients formerly treated with bismuth subcitrate or maintained with cimetidine
41. Campylobacter pylori and ulcer recurrence
42. Influence of ulcer healing agents on ulcer relapse after discontinuation of acute treatment: a pooled estimate of controlled clinical trials
43. Effect of colloidal bismuth (De‐Nol) on healing and relapse of duodenal ulcers—role of Campylobacter pyloridis
44. Long‐term Campylobacter pylori recurrence post eradication
45. Prevention of nitromidazole resistance in Campylobacter pyloridis by co‐administration of colloidal bismuth subcitrate: clinical and in vitro studies
46. Prospective double‐blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori
47. Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication
48. Cure of duodenal ulcer associated with eradication of Helicobucter pylori
49. The effect of Helicobacter pylori on the healing and relapse of duodenal ulcer
50. Cure of duodenal ulcer after eradication of Helicobacter pylori
51. The role of H. pylori eradication on the natural history of duodenal ulcer disease
52. Transfer of Campylobacter pylori and Campylobacter miustelae to Helicobacter gen. nov, as Helicobacter pylori comb. nov. and Helicobacter mustelae comb. nov. respectively
53. Bactriological and pharmacological basis for the treatment of Campylobacter pylori infection
54. Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents
55. Metronidazole resistance in Helicobacter pylori
56. Campylobacter pylori gastritis: long‐term results of treatment with amoxycillin
57. Treatment failure of ofloxacin in Campylobacrter pylori infection
58. Antacids reduce Campylobacter pylori colonization without healing the gastritis in patients with non‐ulcer dyspepsia and erosive prepyloric changes
59. The efficacy of antimicrobial treatment in Cumpylobacter pylori‐associated gastritis and duodenal ulcer
60. Omeprazole, Campylobacter pylori and duodenal ulcer
61. Omeprazole, Helicobacter pylori, gastritis and duodenal ulcer
62. Omeprazole and Helicobacter pylori: temporary suppression rather than true eradication
63. Short report: the effect of omeprazole on Helicobacter pylori and associated gastritis
64. Adjuvant antibiotic therapy in duodenal ulcers treated with colloidal bismuth subcitrate
65. A potential mechanism of action of colloidal bismuth subcitrate: diffusion barrier to hydrochloric acid
66. Studies on the gastroprotective and ulcer healing effects of colloidal bismuth subcitrate
67. De‐Dol stimulates gastric and duodenal alkaline secretion through a prostaglandin dependent mechanism
68. Colloidal bismuth subcitrate (De‐Nol) reduced leukotriene C4 formation in duodenal ulcers (DU)
69. Acid, pepsin and mucin secretion in patients with gastric and duodenal ulcers before and after colloidal bismuth subcitrate (De‐Nol)
70. The safety profile of De‐Nol
71. Efficacy of different dosage regimes in duodenal ulcer healing and eradication of Campylobacter pylori
72. Bismuth pharmacokinetics in the human gastric mucosa
73. Helicobacter pylori infection and duodenal ulcer
74. Helicobacter pylori: causal agent in peptic ulcer disease
75. Role of Campylobacter pyloridis in non‐ulcer dyspepsia. A randomised controlled trial
76. Oral triple therapy may effectively eradicate Campylobacter pylori in man: a pilot study
77. Therapeutic trials of eradication of Campylubacter pylori
78. Triple therapy is not always 95% effective
79. Eradicating Helicobacter pylori and symptoms of non‐ulcer dyspepsia
80. Short‐term regimens to eradicate Helicobacter pylori
81. One week eradication regimen for Helicobacter pylori
82. Dyspepsia: a dilemma for doctors